

# Around the world of U.S. healthcare in 360 words or less

Center for Healthcare Regulatory Insight

#### September 3, 2021 | Issue 187

Editor's note

This note is produced every Friday by the <u>KPMG Center for Healthcare</u> <u>Regulatory Insight</u> and is intended to be short and succinct, no more than 360 words, to provide a digestible bite of healthcare and life sciences news from the past week. Please share this email with colleagues and other interested individuals, and encourage them to <u>subscribe to our mailing list</u> <u>here</u>.

We welcome your feedback. Let us know if KPMG can help. Please <u>reply</u> <u>here to me</u>, **Larry Kocot**, principal and national leader, KPMG Center for Healthcare Regulatory Insight or simply reply to this email with any comments or requests.

Subscribe here 🧹

### Special Supplement: COVID-19 News

In light of the continuing daily volume of COVID-19 activity and news, we have summarized <u>COVID-19 news for the week in this special supplement</u>.

0



Healthcare regulatory news

HHS plans to launch an office focused on <u>health impacts of climate</u> <u>change</u>; hospitals and health systems could <u>face greenhouse gas</u> <u>emissions goals</u>... HHS <u>revoked a Trump Administration policy</u> that limited FDA's ability to independently issue regulations... HHS will <u>quadruple the</u> <u>number of ACA navigators</u> to <u>1,500 across 60 organizations</u>. CMS will <u>restart its non-emergency ambulance transportation</u> prior authorization demonstration expansion December 1.

FDA <u>approved a twice-yearly version of Invega</u>, a Johnson & Johnson schizophrenia treatment.

Two senior vaccine regulators at FDA who were involved in review of COVID-19 vaccine applications <u>plan to leave the agency</u> this fall.

0



#### Healthcare law and policy news

CMS <u>announced</u> Ellen Montz as Director of CCIIO, Natalia Chalmers as the Chief Dental Officer, and Dara Corrigan as Director of CPI.

A bankruptcy judge <u>approved Purdue Pharma's bankruptcy plan</u> shielding Sackler family members from future lawsuits... A Superior Court judge <u>approved Sutter Health's \$575M antitrust settlement</u>; Sutter will also <u>pay</u> <u>\$90M to settle</u> Medicare Advantage False Claims Act allegations... A <u>federal judge ruled</u> against dozens of hospitals that <u>sued HHS to</u> <u>recalculate disproportionate share hospital (DSH)</u> payments.

KPMG, EBG, and FPP reported that <u>year-to-date healthcare and life</u> <u>sciences deals are up 76%</u> from last year... Baxter will <u>acquire Hillrom</u> (<u>\$10.5B</u>)... Boston Scientific <u>acquired Lumenis</u> (<u>\$1B</u>), an Israeli surgical laser business... Catalent <u>will acquire Bettera Holdings</u> (<u>\$1B</u>)... Hackensack Meridian Health and Englewood Health <u>appealed a district</u> <u>court ruling delaying</u> their proposed merger while under FTC review.

CareFirst and Highmark launched an <u>insurance offering designed</u> <u>specifically for labor unions</u> and members... Biogen is offering its Alzheimer's drug <u>Aduhelm to some patients for free</u>... Apple plans to <u>add</u> <u>blood pressure monitoring and a thermometer</u> to its smartwatch. CommonSpirit Health <u>deployed Good Workspace to improve</u> patient and employee collaborations.

Medicare Trustees projected Medicare Trust Fund solvency through 2026, unchanged for the fourth straight year; the pandemic lowered payroll taxes, while <u>non-COVID care spending significantly declined</u>... CDC data show that <u>31.6M Americans (9.7% of the population) lacked health insurance</u> in 2020, down slightly from 33.2M in 2019... Hospital-acquired <u>infections</u> have increased 47% year-over-year.

The Hill reported a bill proposed by Senate Democrats targeted at lowering prescription drug prices <u>may not apply to individuals with employer-</u><u>sponsored coverage</u>.

Questions or comments, please send to <u>ushcinsight@kpmg.com</u>.

Succeeding in the new reality Visit the COVID-19 resource center for KPMG

analysis, insights, and perspectives.

kpmg.com/socialmedia



Privacy | Legal

You have received this message from KPMG LLP. If you wish to unsubscribe from Around the world of U.S. healthcare in 360 words or less, please click here. If you wish to unsubscribe from all KPMG communications, please click here.

KPMG LLP, 3 Chestnut Ridge Road, Montvale, NJ 07645

© 2021 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved. NDP131714-1A

The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization.



# COVID-19 News Supplement

# **Center for Healthcare Regulatory Insight**



# COVID-19 by the Numbers

There have now been <u>roughly 39.5 million confirmed COVID-19 cases</u> in the US, with a death toll over 630,000... New cases <u>averaged 160,000 per day over the past week</u>, up 14% from the week before... The American Academy of Pediatrics reported that an additional <u>roughly 204,000 cases were reported</u> <u>among children last week</u>, up 9% from the previous week.

372 million COVID-19 <u>vaccine doses have been administered</u> in the US (roughly 910,000/day over the past week)... Nearly 206 million Americans (72.5% of Americans 12 and older and 92.2% of Americans 65 and older) have received at least one dose of a COVID-19 vaccine; 175 million Americans are fully vaccinated (61.7% of Americans 12 and older).

CDC Director Rochelle Walensky <u>urged unvaccinated people not to travel</u> over Labor Day weekend... The EU recommended that its <u>member states tighten restrictions on tourists and other nonessential</u> <u>travelers</u> from the US.

## Executive and Administrative Action

The Biden Administration is <u>"sticking with" its recommendation</u> for a third dose of a COVID-19 vaccine eight months, not six months, after the initial dose... An FDA vaccine advisory committee will <u>meet</u> <u>September 17 to discuss COVID-19 booster shots</u>... White House Chief Medical Advisor, Anthony Fauci, indicated that <u>three doses of COVID-19 vaccines could become the standard regimen</u> for most people.

The White House announced <u>\$2.7 billion to expand vaccine manufacturing</u> to help boost global supply.

Secretary of State Tony Blinken and HHS Secretary Xavier Becerra <u>published a joint op-ed in JAMA</u> calling for reforms to make "the world safer from future pandemics."

HRSA renamed and reorganized the Office of Provider Support into a <u>Provider Relief Bureau</u> to manage and distribute COVID-19 Provider Relief Funds.

# Healthcare Regulatory News

CMS <u>released Medicaid and CHIP guidance</u> on <u>increasing vaccination and testing for COVID-19</u>, including encouraging states to offer <u>financial incentives</u> to people on Medicaid who get vaccinated against COVID-19.

CDC warned that providers who administer COVID-19 vaccine booster doses <u>off-label might not be</u> <u>covered by liability protections</u> under the Public Readiness and Emergency Preparedness Act.

#### Healthcare Law, Business, and Policy News

An Economist Intelligence Unit report estimated that <u>the world economy could lose trillions of dollars</u> because of delayed COVID-19 vaccination timelines, particularly in developing countries.

An AP-NORC poll found that <u>59% of remote workers and 47% of those working in-person favor</u> COVID-19 vaccine requirements at their workplaces... An <u>Axios/Ipsos survey found</u> that fewer adults than ever (20%) now say they won't get a COVID-19 vaccine and that 80% of respondents whose employers require a COVID-19 vaccine said they were already vaccinated, as compared to 68% of respondents who employers do not have a vaccine requirement... A Willis Towers Watson survey found that <u>52% of US</u> employers could have some type of COVID-19 vaccine requirement in the workplace by Q4.

A study found that lotteries and other incentives offered by 24 states to increase COVID-19 vaccinations were not associated with a significant change in vaccination rates.

NBC News reported that pharmacies and state governments <u>have discarded 15.1 million unused doses</u> of COVID-19 vaccines since March 1.

### Surveillance, Testing, and Treatment

CDC's Advisory Committee on Immunization Practices (ACIP) <u>unanimously endorsed Pfizer-BioNTech's</u> <u>COVID-19 vaccine</u> for approval, one week after the FDA granted full approval... ACIP also <u>signaled</u> <u>support for offering COVID-19 booster shots</u> to Americans, beginning with healthcare workers, longterm care residents, and other who were previously prioritized in the vaccine campaign.

An Israeli study found that a <u>third shot of Pfizer-BioNTech's COVID-19 vaccine lowered infection risk</u> by 48% to 68% a week to 13 days later.

Moderna is <u>seeking authorization for a booster dose of its COVID-19 vaccine</u>... Moderna and Takeda are working with Japanese authorities to <u>recall three batches of COVID-19 vaccines</u> after an investigation discovered stainless steel contaminants in some vials.

A COVID-19 vaccine being co-developed by GlaxoSmithKline and SKBioscience <u>is entering a late-stage</u> <u>clinical trial</u>.

NIAID <u>launched a clinical trial</u> to study COVID-19 booster vaccines in individuals with autoimmune diseases, such as lupus and multiple sclerosis.

Former FDA Commissioner Scott Gottlieb said COVID-19 <u>vaccines for children younger than 12 could be</u> <u>approved</u> as soon as November.

Late last week, FDA <u>changed the emergency use authorization for Eli Lilly's combo COVID-19 monoclonal</u> <u>antibody treatment</u> to authorize use in in states, territories, and U.S. jurisdictions where the combined frequency of variants resistant to the product is less than or equal to 5%; based on data from this week, all states meet that criteria and HHS resumed distribution of product across the country.

Pfizer and Merck <u>announced new clinical trials</u> of their respective oral antiviral therapies for COVID-19.